Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.66 +0.48 (+1.00%)
Streaming Delayed Price Updated: 9:49 AM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 165,725
Open 48.72
Bid (Size) 48.65 (2)
Ask (Size) 48.67 (16)
Prev. Close 48.18
Today's Range 48.60 - 48.94
52wk Range 45.80 - 60.12
Shares Outstanding 1,250,690,553
Dividend Yield 4.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%. 
Via Stocktwits
Topics ETFs Government Stocks
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025. 
Via Benzinga

Performance

YTD
+1.0%
+1.0%
1 Month
-2.2%
-2.2%
3 Month
-2.4%
-2.4%
6 Month
-2.4%
-2.4%
1 Year
-3.1%
-3.1%

More News

Read More
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
Via Investor's Business Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Via MarketBeat
Why This Biotech Stock Just Doubled In A Single Day
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
Via Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Via Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
Via Stocktwits
Topics Supply Chain
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
From Brodsky & Smith LLC
Via GlobeNewswire

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 48.66
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 07/09/25 09:49 AM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 60.86B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 61B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.